Recombinant factor VIIa (NovoSeven) for prevention and treatment of bleeding in patients with underlying disease - horizon scanning review
NHSC
Record ID 32004000140
English
Authors' objectives:
This study aims to assess the effectiveness of recombinant factor VIIa (NovoSeven) for prevention and treatment of bleeding in patients with underlying disease.
Authors' recommendations:
Recombinant factor VIIa (rFVIIa, NovoSeven) is currently available in the UK for treatment of spontaneous and surgical bleeding in patients with haemophilia and inhibitors to factors VIII and IX. Studies of rFVIIa in patients with liver disease undergoing laparoscopic liver biopsy (uncontrolled, dose-ranging), in patients undergoing liver transplantation (using historical controls), found that transfusion requirements were reduced. Other indications under investigation include its use to stop massive life-threatening bleeding from trauma and surgical bleeding.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2003
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Blood Coagulation Factors
- Factor VIIa
- Hemophilia A
- Recombinant Proteins
- Hemorrhage
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.